Drug intelligence / Profile preview

ICA-03

Development stage: Preclinical
Lead developer: iCamuno Biotherapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

ICA-03 is an induced pluripotent stem cell (iPSC) based drug candidate currently in preclinical development by iCamuno Biotherapeutics Ltd. It is being investigated for the treatment of osteoarthritis. As an iPSC-based therapy, its mechanism is expected to involve the regenerative and reparative capabilities of these pluripotent cells, potentially differentiating into relevant cell types to repair damaged tissues and modulate the local microenvironment in affected joints.

Beyond the preview

Go deeper on ICA-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICA-03.

Explore the full profile